Filters

 

Resource Type
Novel K+ channel targets in atrial fibrillation drug development: where are we?

El-Haou, S.; Ford, J.; Milnes, J. Journal of Cardiovascular Pharmacology. 2015, 66 (5), 412-431

Read More
Using high quality HTS automated patch-clamp data from human cardiac ion channels and in silico action potential modelling to cost-effectively predict QP prolongation and arrhythmia risk for CiPA

Presentation by Marc Rogers (Metrion CSO) at the September 2015 Safety Pharmacological Society, Prague. Using high quality HTS automated patch-clamp data from human cardiac ion channels and in silico action potential modelling to cost-effectively predict QP prolongation and arrhythmia risk for CiPA.

Read More
Developing a package of in vitro human cardiac ion channel assays using automated patch-clamp to predict clinical arrhythmia risk

Current cardiac safety testing regimes have successfully prevented new drugs coming to market with unknown proarrhythmic risk. However, they are expensive and time-consuming, and an over-reliance on hERG liability as a marker for proarrhythmia has led to exclusion of useful chemical scaffolds from further drug development. In addition, the focus on hERG ignores the risk posed by potential drug interactions with multiple cardiac ion channels (MICE) that can alter cardiac action potentials.

Read More
Optimising a difficult Nav1.8 cell line assay for automated patch-clamp screening

The TTX-resistant sodium channel Nav1.8 is expressed in peripheral sensory nociceptors and is implicated in a range of inflammatory and visceral pain conditions such as irritable bowel syndrome (IBS)1. Nav1.8 channel function in sensory neurons changes after injury or inflammation, with a redistribution from the soma to axons and upregulated activity through inflammatory mediators and signalling pathways.

Read More
Atrial‐like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial‐selective pharmacology

Devalla, H.D.; Schwach, V.; Ford, J.W.; Milnes, J.T.; El‐Haou, S.; Jackson, C.; Gkatzis, K.; Elliott, D.A.; de Sousa Lopes, S.M.C.; Mummery, C.L.; Verkerk, A.O.; Passier, R. EMBO Molecular Medicine 2015. 7 (4), 394-410

Read More
Synthesis and biological evaluation of piperazine derivatives as novel isoform selective voltage-gated sodium (Nav) 1.3 channel modulators

Jukič, M.; Frlan, R.; Chan, F.; Kirby, R.W.; Madge, D.J.; Tytgat, J.; Peigneur, S.; Anderluh, M.; Kikelj, D. Medicinal Chemistry Research. 2015, 24 (6), 2366-2380

Read More
Open access to the KCNQ channel: Retigabine and second generation M-current openers
Read More
Action of Clathrodin and Analogues on Voltage-Gated Sodium Channels

Peigneur, S.; Žula, A.; Zidar, N.; Chan-Porter, F.; Kirby, R.; Madge, D.; Ilaš, J.; Kikelj, D.; Tytgat, J. Marine Drugs. 2014, 12(4), 2132-43

Read More
Ligand- and structure-based virtual screening for clathrodin-derived human voltage-gated sodium channel modulators

Tomašić, T.; Hartzoulakis. B.; Zidar. N.; Chan, F.; Kirby R.W.; Madge, D.J.; Peigneur, S.; Tytgat, J.; Kikelj, D. Journal of Chemical Information and Modelling. 2013, 53 (12), 3223-32

Read More
Novel state-dependent voltage-gated sodium channel modulators, based on marine alkaloids from Agelas sponges

Hodnik, Ž.; Tomašić, T.; Mašič L.P.; Chan, F.; Kirby, R.W.; Madge D.J.; Kikelj, D. European Journal of Medicinal Chemistry. 2013, 70, 154-64

Read More
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram